Robert M. Forrester
Founder at EQRx International, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Melanie I. Nallicheri | F | 56 |
EQRx International, Inc.
EQRx International, Inc. Pharmaceuticals: MajorHealth Technology EQRx International, Inc. engages in healthcare services. The firm specializes in remaking medicine services. The company was founded by Peter Bach and Sandra Horning on January 12, 2020 and is headquartered in Cambridge, MA. | 5 years |
Alexis Borisy | M | 52 |
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA
EQRx International, Inc.
EQRx International, Inc. Pharmaceuticals: MajorHealth Technology EQRx International, Inc. engages in healthcare services. The firm specializes in remaking medicine services. The company was founded by Peter Bach and Sandra Horning on January 12, 2020 and is headquartered in Cambridge, MA. | 15 years |
Gang Song | M | - |
Pillar Biosciences, Inc.
Pillar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Pillar Biosciences, Inc. is a clinical cancer diagnostics company. The firm engages in the creation of precision NGS panels and software solutions. It offers solid tumor panels, blood cancer panels, inherited disease panels, and custom panels. The company was founded by Gang Song and Zhaohui Wang in 2014 and is headquartered in Natick, MA.
Affyimmune Therapeutics, Inc.
Affyimmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Affyimmune Therapeutics, Inc. engages in the development of engineered immune cells to fight cancer disease. The company was founded by Gang Song on August 16, 2016 and is headquartered in Natick, MA. | 10 years |
Sameer A. Sabir | M | - |
Eyecool Therapeutics, Inc.
Eyecool Therapeutics, Inc. Medical SpecialtiesHealth Technology Eyecool Therapeutics, Inc. develops novel device-based technology for the treatment of dry eye. The company is based in Cambridge, MA.
Brixton Biosciences, Inc.
Brixton Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Brixton Biosciences, Inc. has developed coolio™ therapy, an injection that provides long-lasting pain relief as an alternative to opioids. The company is based in Cambridge, MA and was founded by Robert M. Forrester and Sameer A. Sabir. The therapy is designed to desensitize pain in a targeted area and has the potential to eradicate the pain of pain. | - |
Daniel Calkins | M | 37 | 6 years | |
Michael Kauffman | M | 60 |
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | 16 years |
Ben Auspitz | M | - |
IDRx, Inc.
IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | - |
Matt Britz | M | - |
Affyimmune Therapeutics, Inc.
Affyimmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Affyimmune Therapeutics, Inc. engages in the development of engineered immune cells to fight cancer disease. The company was founded by Gang Song on August 16, 2016 and is headquartered in Natick, MA. | 3 years |
Bing Yuan | M | - |
OnCusp Therapeutics6
OnCusp Therapeutics6 Miscellaneous Commercial ServicesCommercial Services OnCusp Therapeutics is a biotechnology company based in New York, NY and has subsidiaries in China. OnCusp Therapeutics specializes in developing preclinical assets to clinical proof of concept and then partnering out for commercialization in the field of oncology therapeutics. The company is committed to accelerating the advancement of oncology assets by leveraging its deep translational and clinical development expertise. OnCusp Therapeutics is backed by prominent investors including Sequoia Capital, Biotrack Capital, Oriza Seed Capital, and AIHC Capital. The company was founded in 2021 by Andy Fu, Bing Yuan, and Eric Slosberg, with Bing Yuan serving as the CEO since then. | - |
Robin Mansukhani | M | - |
Deciduous Therapeutics, Inc.
Deciduous Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA. | - |
Brian Stuglik | M | 64 | 7 years | |
Jorge Conde | M | 47 |
IDRx, Inc.
IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | 4 years |
Kathryn E. Giusti | F | 65 |
EQRx International, Inc.
EQRx International, Inc. Pharmaceuticals: MajorHealth Technology EQRx International, Inc. engages in healthcare services. The firm specializes in remaking medicine services. The company was founded by Peter Bach and Sandra Horning on January 12, 2020 and is headquartered in Cambridge, MA. | 3 years |
Eric Slosberg | M | - |
OnCusp Therapeutics6
OnCusp Therapeutics6 Miscellaneous Commercial ServicesCommercial Services OnCusp Therapeutics is a biotechnology company based in New York, NY and has subsidiaries in China. OnCusp Therapeutics specializes in developing preclinical assets to clinical proof of concept and then partnering out for commercialization in the field of oncology therapeutics. The company is committed to accelerating the advancement of oncology assets by leveraging its deep translational and clinical development expertise. OnCusp Therapeutics is backed by prominent investors including Sequoia Capital, Biotrack Capital, Oriza Seed Capital, and AIHC Capital. The company was founded in 2021 by Andy Fu, Bing Yuan, and Eric Slosberg, with Bing Yuan serving as the CEO since then. | - |
Eli Casdin | M | 51 |
IDRx, Inc.
IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | 3 years |
Joshua Phillips | M | 57 |
SevenOaks Biosystems LLC
SevenOaks Biosystems LLC Medical SpecialtiesHealth Technology Part of Medline Industries LP (Illinois), SevenOaks Biosystems LLC is a company that develops medical devices. The company is based in Cambridge, MA. The company was founded by Richard Rox Anderson, Sameer A. Sabir. SevenOaks Biosystems was acquired by Medline Industries LP (Illinois) on November 30, 2016.
Eyecool Therapeutics, Inc.
Eyecool Therapeutics, Inc. Medical SpecialtiesHealth Technology Eyecool Therapeutics, Inc. develops novel device-based technology for the treatment of dry eye. The company is based in Cambridge, MA.
Brixton Biosciences, Inc.
Brixton Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Brixton Biosciences, Inc. has developed coolio™ therapy, an injection that provides long-lasting pain relief as an alternative to opioids. The company is based in Cambridge, MA and was founded by Robert M. Forrester and Sameer A. Sabir. The therapy is designed to desensitize pain in a targeted area and has the potential to eradicate the pain of pain. | 10 years |
Richard Paul Kivel | M | 57 |
Rhapsody Biologics, Inc.
Rhapsody Biologics, Inc. BiotechnologyHealth Technology Rhapsody Biologics, Inc. develops a personalized peptide vaccine platform. It predicts and optimizes peptide vaccines for use at an individual and population level. Its platform technology encompasses a discovery system to identify immunogenic fragments of disease causing agents that will stimulate an immune response. The company was founded by Richard Paul Kivel and Ren Ee Chee in October 2009 and is headquartered in Norwell, MA. | 15 years |
Paul Berns | M | 57 |
EQRx International, Inc.
EQRx International, Inc. Pharmaceuticals: MajorHealth Technology EQRx International, Inc. engages in healthcare services. The firm specializes in remaking medicine services. The company was founded by Peter Bach and Sandra Horning on January 12, 2020 and is headquartered in Cambridge, MA. | 4 years |
Zhaohui Wang | M | - |
Pillar Biosciences, Inc.
Pillar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Pillar Biosciences, Inc. is a clinical cancer diagnostics company. The firm engages in the creation of precision NGS panels and software solutions. It offers solid tumor panels, blood cancer panels, inherited disease panels, and custom panels. The company was founded by Gang Song and Zhaohui Wang in 2014 and is headquartered in Natick, MA. | 10 years |
Hong Fang Song | M | - |
Affyimmune Therapeutics, Inc.
Affyimmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Affyimmune Therapeutics, Inc. engages in the development of engineered immune cells to fight cancer disease. The company was founded by Gang Song on August 16, 2016 and is headquartered in Natick, MA. | - |
Andy Fu | M | - |
OnCusp Therapeutics6
OnCusp Therapeutics6 Miscellaneous Commercial ServicesCommercial Services OnCusp Therapeutics is a biotechnology company based in New York, NY and has subsidiaries in China. OnCusp Therapeutics specializes in developing preclinical assets to clinical proof of concept and then partnering out for commercialization in the field of oncology therapeutics. The company is committed to accelerating the advancement of oncology assets by leveraging its deep translational and clinical development expertise. OnCusp Therapeutics is backed by prominent investors including Sequoia Capital, Biotrack Capital, Oriza Seed Capital, and AIHC Capital. The company was founded in 2021 by Andy Fu, Bing Yuan, and Eric Slosberg, with Bing Yuan serving as the CEO since then. | - |
Ren Ee Chee | M | - |
Rhapsody Biologics, Inc.
Rhapsody Biologics, Inc. BiotechnologyHealth Technology Rhapsody Biologics, Inc. develops a personalized peptide vaccine platform. It predicts and optimizes peptide vaccines for use at an individual and population level. Its platform technology encompasses a discovery system to identify immunogenic fragments of disease causing agents that will stimulate an immune response. The company was founded by Richard Paul Kivel and Ren Ee Chee in October 2009 and is headquartered in Norwell, MA. | 15 years |
Eric Rowinsky | M | 67 | 7 years | |
Vincent A. Miller | M | 62 |
EQRx International, Inc.
EQRx International, Inc. Pharmaceuticals: MajorHealth Technology EQRx International, Inc. engages in healthcare services. The firm specializes in remaking medicine services. The company was founded by Peter Bach and Sandra Horning on January 12, 2020 and is headquartered in Cambridge, MA. | 4 years |
Chau Khuong | M | 48 |
OnCusp Therapeutics6
OnCusp Therapeutics6 Miscellaneous Commercial ServicesCommercial Services OnCusp Therapeutics is a biotechnology company based in New York, NY and has subsidiaries in China. OnCusp Therapeutics specializes in developing preclinical assets to clinical proof of concept and then partnering out for commercialization in the field of oncology therapeutics. The company is committed to accelerating the advancement of oncology assets by leveraging its deep translational and clinical development expertise. OnCusp Therapeutics is backed by prominent investors including Sequoia Capital, Biotrack Capital, Oriza Seed Capital, and AIHC Capital. The company was founded in 2021 by Andy Fu, Bing Yuan, and Eric Slosberg, with Bing Yuan serving as the CEO since then. | 1 years |
Max Krummel | M | - |
Deciduous Therapeutics, Inc.
Deciduous Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA. | 3 years |
Randy Pritchard | M | - |
Pillar Biosciences, Inc.
Pillar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Pillar Biosciences, Inc. is a clinical cancer diagnostics company. The firm engages in the creation of precision NGS panels and software solutions. It offers solid tumor panels, blood cancer panels, inherited disease panels, and custom panels. The company was founded by Gang Song and Zhaohui Wang in 2014 and is headquartered in Natick, MA. | 3 years |
William McCullen | M | - |
Eyecool Therapeutics, Inc.
Eyecool Therapeutics, Inc. Medical SpecialtiesHealth Technology Eyecool Therapeutics, Inc. develops novel device-based technology for the treatment of dry eye. The company is based in Cambridge, MA. | - |
Robert Charles Pozen | M | 76 |
Brixton Biosciences, Inc.
Brixton Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Brixton Biosciences, Inc. has developed coolio™ therapy, an injection that provides long-lasting pain relief as an alternative to opioids. The company is based in Cambridge, MA and was founded by Robert M. Forrester and Sameer A. Sabir. The therapy is designed to desensitize pain in a targeted area and has the potential to eradicate the pain of pain. | - |
Eric Lai | M | 67 |
Pillar Biosciences, Inc.
Pillar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Pillar Biosciences, Inc. is a clinical cancer diagnostics company. The firm engages in the creation of precision NGS panels and software solutions. It offers solid tumor panels, blood cancer panels, inherited disease panels, and custom panels. The company was founded by Gang Song and Zhaohui Wang in 2014 and is headquartered in Natick, MA. | 3 years |
Scott Aaron Kupor | M | - |
EQRx International, Inc.
EQRx International, Inc. Pharmaceuticals: MajorHealth Technology EQRx International, Inc. engages in healthcare services. The firm specializes in remaking medicine services. The company was founded by Peter Bach and Sandra Horning on January 12, 2020 and is headquartered in Cambridge, MA. | 4 years |
Hagop Youssoufian | M | 67 | 7 years | |
Rachel Hatano | F | - |
Deciduous Therapeutics, Inc.
Deciduous Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA. | - |
Anil Bhushan | M | - |
Deciduous Therapeutics, Inc.
Deciduous Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA. | - |
Dylan Morris | M | - |
Deciduous Therapeutics, Inc.
Deciduous Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA. | - |
Leah Makley | M | - |
Deciduous Therapeutics, Inc.
Deciduous Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA. | 2 years |
Shawn Liu | M | - |
Pillar Biosciences, Inc.
Pillar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Pillar Biosciences, Inc. is a clinical cancer diagnostics company. The firm engages in the creation of precision NGS panels and software solutions. It offers solid tumor panels, blood cancer panels, inherited disease panels, and custom panels. The company was founded by Gang Song and Zhaohui Wang in 2014 and is headquartered in Natick, MA. | - |
Hui Yang | M | - |
Pillar Biosciences, Inc.
Pillar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Pillar Biosciences, Inc. is a clinical cancer diagnostics company. The firm engages in the creation of precision NGS panels and software solutions. It offers solid tumor panels, blood cancer panels, inherited disease panels, and custom panels. The company was founded by Gang Song and Zhaohui Wang in 2014 and is headquartered in Natick, MA. | - |
Hong Fang Sang | M | - |
Pillar Biosciences, Inc.
Pillar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Pillar Biosciences, Inc. is a clinical cancer diagnostics company. The firm engages in the creation of precision NGS panels and software solutions. It offers solid tumor panels, blood cancer panels, inherited disease panels, and custom panels. The company was founded by Gang Song and Zhaohui Wang in 2014 and is headquartered in Natick, MA. | - |
Martin Zillmann | M | - |
Pillar Biosciences, Inc.
Pillar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Pillar Biosciences, Inc. is a clinical cancer diagnostics company. The firm engages in the creation of precision NGS panels and software solutions. It offers solid tumor panels, blood cancer panels, inherited disease panels, and custom panels. The company was founded by Gang Song and Zhaohui Wang in 2014 and is headquartered in Natick, MA. | - |
Jonathan Pachter | M | 66 | 13 years | |
Tasneem Dohadwala | F | - |
Brixton Biosciences, Inc.
Brixton Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Brixton Biosciences, Inc. has developed coolio™ therapy, an injection that provides long-lasting pain relief as an alternative to opioids. The company is based in Cambridge, MA and was founded by Robert M. Forrester and Sameer A. Sabir. The therapy is designed to desensitize pain in a targeted area and has the potential to eradicate the pain of pain. | 5 years |
Christoph S. Lengauer | M | 59 |
IDRx, Inc.
IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | - |
Josh Tolkoff | M | - |
Eyecool Therapeutics, Inc.
Eyecool Therapeutics, Inc. Medical SpecialtiesHealth Technology Eyecool Therapeutics, Inc. develops novel device-based technology for the treatment of dry eye. The company is based in Cambridge, MA. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Robert J. Lollini | M | 71 | 3 years | |
Justin Renz | M | 52 |
Coley Pharmaceutical Group, Inc.
Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | 12 years |
Paul Brannelly | M | 51 |
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | 7 years |
David Gryska | M | 68 | - | |
Mark Corrigan | M | 66 |
Neuromed Pharmaceuticals Ltd.
Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC.
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | 1 years |
Joseph Chiapponi | M | 55 | 6 years | |
Jason Aryeh | M | 56 | 3 years | |
Moonsoo Jin | M | - |
Affyimmune Therapeutics, Inc.
Affyimmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Affyimmune Therapeutics, Inc. engages in the development of engineered immune cells to fight cancer disease. The company was founded by Gang Song on August 16, 2016 and is headquartered in Natick, MA. | - |
W. Wayne Laslie | M | 79 | 3 years | |
Adrian N. Hobden | M | 71 | 13 years | |
Sandra Horning | M | 75 | 4 years | |
Richard H. Aldrich | M | 69 | 4 years | |
Christopher C. Gallen | M | 72 |
Neuromed Pharmaceuticals Ltd.
Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC.
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | 6 years |
John A. Sedor | M | 80 |
CPEX Pharmaceuticals, Inc.
CPEX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology CPEX Pharmaceuticals, Inc. is engaged in the development, licensing and commercialization of pharmaceutical products utilizing its validated drug delivery technology. Its technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through formulation development with proprietary molecules such as CPE-215. The company's first product is Testim, a gel for testosterone replacement therapy, which is a formulation of its technology with testosterone. Testim is licensed to Auxilium Pharmaceuticals, Inc., which is currently marketing it in the United States, Europe and other countries. Its other product is Nasulin, which is an intranasal formulation of insulin being developed to treat hyperglycemia in patients suffering from Type 1 and Type 2 diabetes. The company was founded on September 28, 2007 and is headquartered in Exeter, NH. | 3 years |
Richard B. Brewer | M | 72 | - | |
Charles E. Yon | M | - |
Coley Pharmaceutical Group, Inc.
Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | - |
Curtis T. Keith | M | 53 |
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | 8 years |
Terrance P. Snutch | M | - |
Neuromed Pharmaceuticals Ltd.
Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC. | 15 years |
Dennis P. Cameron | M | - |
MeesPierson, Inc.
| 3 years |
Barbara H. Deptula | F | 69 |
Coley Pharmaceutical Group, Inc.
Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | 8 years |
Stephen Kraus | M | 47 | 2 years | |
Chuck Yon | M | - |
Coley Pharmaceutical Group, Inc.
Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | 7 years |
Robert Oliver | M | 65 | - | |
Dina Ciarimboli | F | - | 1 years | |
Timothy Franson | M | 72 | 4 years | |
John Doyle | M | 46 | 2 years | |
Krishna Yeshwant | M | 46 | 3 years | |
Amy P. Abernethy | M | 56 | - | |
Sean Flynn | M | 50 | 1 years | |
Alison Lawton | F | 62 | 8 years | |
Andrew Gibbs | M | 49 | 2 years | |
Stephen Sherwin | M | 75 | 3 years | |
Paul Friedman | M | 81 | 3 years | |
Don C. Stark | M | 69 | 12 years | |
Jason Cole | M | 51 |
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | 5 years |
Bruce Wendel | M | 70 | 5 years | |
Edward Swabb | M | 76 | 1 years | |
S. Phanstiel | F | 65 | 6 years | |
Samuel Merksamer | M | 43 | - | |
Gina Consylman | F | 52 | 3 years | |
Timothy Barberich | M | 76 | 8 years | |
Henri A. Termeer | M | 78 | 5 years | |
Frank W. Haydu | M | 76 |
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | 6 years |
Clive Meanwell | M | 67 | 3 years | |
Ansbert Gadicke | M | 66 | 2 years | |
Lynn G. Baird | M | 76 |
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | 3 years |
Geoffrey F. Cox | M | 80 | - | |
Hartley Richardson | M | 69 |
Neuromed Pharmaceuticals Ltd.
Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC.
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | 1 years |
Bill Hunter | M | 61 |
Neuromed Pharmaceuticals Ltd.
Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC.
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | 1 years |
Mary E. Paetzold | F | 74 | 16 years | |
John Henderson | M | 79 | 4 years | |
Jami Rubin | F | 60 | 2 years | |
Peter A. Pellegrino | M | 49 | 1 years | |
Robert Gagnon | M | 49 | 4 years | |
Kirk Taylor | M | - | 1 years | |
Robert Morgan | M | - | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 99 | 99.00% |
Canada | 5 | 5.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Robert M. Forrester
- Personal Network